2cureX AB (publ) (2CUREX.ST)
SEK 0.4
(-5.24%)
SEK 0.4
(-5.24%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -13.4 Million SEK | 70.15% |
| 2022 | -44.89 Million SEK | 38.45% |
| 2021 | -72.94 Million SEK | -24.52% |
| 2020 | -58.57 Million SEK | -73.72% |
| 2019 | -33.72 Million SEK | -68.07% |
| 2018 | -20.06 Million SEK | -0.39% |
| 2017 | -19.98 Million SEK | -171.71% |
| 2016 | -7.35 Million SEK | -18.57% |
| 2015 | -6.2 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -3.12 Million SEK | 76.65% |
| 2024 Q2 | -3.12 Million SEK | 0.0% |
| 2023 Q1 | -34.82 Million SEK | 22.42% |
| 2023 Q4 | -13.4 Million SEK | 25.97% |
| 2023 FY | -13.4 Million SEK | 70.15% |
| 2023 Q3 | -18.1 Million SEK | 31.15% |
| 2023 Q2 | -26.29 Million SEK | 24.51% |
| 2022 Q3 | -47.82 Million SEK | 13.97% |
| 2022 Q1 | -63.34 Million SEK | 13.15% |
| 2022 FY | -44.89 Million SEK | 38.45% |
| 2022 Q4 | -44.89 Million SEK | 6.12% |
| 2022 Q2 | -55.58 Million SEK | 12.26% |
| 2021 Q2 | -78.91 Million SEK | -46.16% |
| 2021 Q1 | -53.99 Million SEK | 7.83% |
| 2021 Q3 | -72.49 Million SEK | 8.13% |
| 2021 Q4 | -72.94 Million SEK | -0.61% |
| 2021 FY | -72.94 Million SEK | -24.52% |
| 2020 Q1 | -30.01 Million SEK | 10.98% |
| 2020 FY | -58.57 Million SEK | -73.72% |
| 2020 Q2 | -30.07 Million SEK | -0.17% |
| 2020 Q4 | -58.57 Million SEK | 8.44% |
| 2020 Q3 | -63.97 Million SEK | -112.76% |
| 2019 Q1 | -17.16 Million SEK | 14.43% |
| 2019 Q4 | -33.72 Million SEK | 12.77% |
| 2019 Q2 | -34.1 Million SEK | -98.67% |
| 2019 Q3 | -38.65 Million SEK | -13.34% |
| 2019 FY | -33.72 Million SEK | -68.07% |
| 2018 Q3 | -23.84 Million SEK | 14.33% |
| 2018 FY | -20.06 Million SEK | -0.39% |
| 2018 Q4 | -20.06 Million SEK | 15.87% |
| 2018 Q2 | -27.83 Million SEK | 9.25% |
| 2018 Q1 | -30.67 Million SEK | -53.49% |
| 2017 Q3 | -4.81 Million SEK | 0.0% |
| 2017 FY | -19.98 Million SEK | -171.71% |
| 2017 Q1 | 7.6 Million SEK | 203.41% |
| 2017 Q4 | -19.98 Million SEK | -314.82% |
| 2016 FY | -7.35 Million SEK | -18.57% |
| 2016 Q4 | -7.35 Million SEK | 0.0% |
| 2015 FY | -6.2 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 73.205% |
| Ziccum AB (publ) | -2.13 Million SEK | -527.188% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | 29.68% |
| BioArctic AB (publ) | -606.58 Million SEK | 97.79% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 73.159% |
| Mendus AB (publ) | -96.29 Million SEK | 86.081% |
| Genovis AB (publ.) | -43.94 Million SEK | 69.498% |
| Intervacc AB (publ) | -88.16 Million SEK | 84.797% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 165.349% |
| Active Biotech AB (publ) | -33.2 Million SEK | 59.63% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 125.183% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 65.967% |
| Aptahem AB (publ) | 2.9 Million SEK | 560.799% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 95.983% |
| Kancera AB (publ) | -45.69 Million SEK | 70.667% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 95.927% |
| Fluicell AB (publ) | -2.76 Million SEK | -385.089% |
| Saniona AB (publ) | 40.44 Million SEK | 133.137% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 58.02% |
| Biovica International AB (publ) | -58.73 Million SEK | 77.181% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 70.358% |
| AcouSort AB (publ) | -23.98 Million SEK | 44.122% |
| Xintela AB (publ) | -7.8 Million SEK | -71.635% |
| Abliva AB (publ) | -57.24 Million SEK | 76.585% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 93.116% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 83.695% |
| OncoZenge AB (publ) | -12.62 Million SEK | -6.146% |
| Amniotics AB (publ) | -5.63 Million SEK | -137.979% |
| CombiGene AB (publ) | -101.44 Million SEK | 86.787% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -520.222% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 348.204% |
| Camurus AB (publ) | -1.16 Billion SEK | 98.85% |
| Corline Biomedical AB | -17.01 Million SEK | 21.214% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 83.995% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 90.298% |
| I-Tech AB | -83.26 Million SEK | 83.903% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 109.95% |
| Cyxone AB (publ) | -16.67 Million SEK | 19.598% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 76.017% |
| Biosergen AB | -1.88 Million SEK | -611.79% |
| Cantargia AB (publ) | -139.74 Million SEK | 90.409% |
| NextCell Pharma AB | -46.79 Million SEK | 71.355% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 89.65% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 54.385% |
| Nanologica AB (publ) | -9.38 Million SEK | -42.767% |
| SynAct Pharma AB | -61.75 Million SEK | 78.298% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | 37.413% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -1.314% |
| LIDDS AB (publ) | -13.51 Million SEK | 0.807% |
| Lipum AB (publ) | -8.46 Million SEK | -58.334% |
| BioInvent International AB (publ) | -236.3 Million SEK | 94.328% |
| Alzinova AB (publ) | -21.22 Million SEK | 36.856% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 79.972% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -158.699% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 83.995% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -1352.113% |
| Simris Alg AB (publ) | 85.07 Million SEK | 115.754% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 83.672% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 108.07% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | 35.541% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -350.976% |